---
title: Efficacy and Safety of Donidalorsen for Hereditary Angioedema
date: '2024-05-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38819395/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240601181228&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Donidalorsen treatment reduced the hereditary angioedema
  attack rate, a finding that supports potential prophylactic use for hereditary angioedema.
  (Funded by Ionis Pharmaceuticals; OASIS-HAE ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Donidalorsen treatment reduced the hereditary angioedema attack rate, a finding that supports potential prophylactic use for hereditary angioedema. (Funded by Ionis Pharmaceuticals; OASIS-HAE ClinicalTrials.gov number, ...